

# CITATION REPORT

List of articles citing

Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian pTreatment of Erectile Dysfunctionpobservational study

DOI: 10.1111/j.1464-410x.2006.06384.x  
BJU International, 2006, 98, 623-9.

**Source:** <https://exaly.com/paper-pdf/40359293/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Bibliography. Current world literature. Reconstructive surgery. <i>Current Opinion in Urology</i> , <b>2007</b> , 17, 439-49		21
21	The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. <i>BJU International</i> , <b>2007</b> , 99, 376-82	5.6	21
20	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 1850-62	2.9	27
19	Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 1198-1207	1.1	47
18	Tadalafil versus sildenafil citrate in the treatment of ED: Italian patients' preferences and explanatory notes. <i>Urologia</i> , <b>2008</b> , 75, 24-31	1.2	1
17	Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 257-67	1.1	13
16	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. <i>Asian Journal of Andrology</i> , <b>2009</b> , 11, 629-37	2.8	1
15	Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. <i>BJU International</i> , <b>2009</b> , 103, 1212-7	5.6	39
14	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3486-95	3.3	16
13	Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2209-2216	1.1	20
12	Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. <i>International Journal of Impotence Research</i> , <b>2011</b> , 23, 1-8	2.3	17
11	Estudio de la eficacia y preferencia de los pacientes con disfunción eréctil grave después de tomar los 3 inhibidores de la fosfodiesterasa 5. <i>Revista Internacional De Andrología</i> , <b>2012</b> , 10, 139-146	0.6	2
10	Tratando la disfunción eréctil en atención primaria (estudio TRADE-AP): efectividad de la toma a demanda de tadalafilo versus pauta diaria. <i>Revista Internacional De Andrología</i> , <b>2012</b> , 10, 63-68	0.6	
9	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , <b>2013</b> , 67, 768-80	2.9	73
8	Preference for erectile dysfunction treatments: Assessment by means of consumers' preference analysis techniques. <i>Actas Urológicas Españolas (English Edition)</i> , <b>2014</b> , 38, 319-326	0.1	
7	Preference for erectile dysfunction treatments: Assessment by means of consumers' preference analysis techniques. <i>Actas Urológicas Españolas</i> , <b>2014</b> , 38, 319-26	0.7	
6	An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. <i>Asian Journal of Andrology</i> , <b>2016</b> , 18, 773-9	2.8	10

5	The role of the sexual partner in managing erectile dysfunction. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 168-73.5	33
4	Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic. <i>Archivio Italiano Di Urologia Andrologia</i> , <b>2021</b> , 93, 361-365	1.6 3
3	An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. <i>Asian Journal of Andrology</i> , <b>2015</b> , 17, 61-7	2.8 12
2	A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. <i>Asian Journal of Andrology</i> , <b>2017</b> , 19, 500-504	2.8 5
1	Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. <i>Patient Preference and Adherence</i> , <b>2008</b> , 2, 149-55	2.4 7